2023
Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
Zhuang W, Zhang W, Xie L, Wang L, Li Y, Wang Z, Zhang A, Qiu H, Feng J, Zhang B, Hu Y. Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. International Journal Of Molecular Sciences 2023, 24: 17631. PMID: 38139459, PMCID: PMC10743877, DOI: 10.3390/ijms242417631.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesSortilin 1Breast tumorsTumor antigen heterogeneityAdvanced breast tumorsSuperior safety profileAnti-tumor activityBreast tumor cell linesSafety profileADC targetBreast cancerCell cytotoxicityBystander killingTumor cell linesDrug resistanceAntigen heterogeneityTumorsPromising targetNew targetsTreatmentCell linesHER2Effective cytotoxicityTumor suppressionLysosomal traffickingNmes1 is a novel regulator of mucosal response influencing intestinal healing potential
Hamley M, Leyk S, Casar C, Liebold I, Al Jawazneh A, Lanzloth C, Böttcher M, Haas H, Richardt U, Rothlin C, Jacobs T, Huber S, Adlung L, Pelczar P, Henao‐Mejia J, Bosurgi L. Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential. European Journal Of Immunology 2023, 54: e2350434. PMID: 37971166, DOI: 10.1002/eji.202350434.Peer-Reviewed Original ResearchMucosal healingSchistosoma mansoni infectionCytokines IL-4Innovative therapeutic approachesDifferent intestinal diseasesWound-healing potentialIntestinal damageMucosal responsesMansoni infectionInflamed colonIL-4Intestinal disordersIntestinal diseaseNormal mucosaMurine modelTherapeutic approachesNovel regulatorType 2Advanced stageTherapy efficacyMacrophage responseCell therapyHealing potentialNew targetsIntestinal regenerationISPD Catheter-related Infection Recommendations: 2023 Update
Chow K, Li P, Cho Y, Abu-Alfa A, Bavanandan S, Brown E, Cullis B, Edwards D, Ethier I, Hurst H, Ito Y, de Moraes T, Morelle J, Runnegar N, Saxena A, So S, Tian N, Johnson D. ISPD Catheter-related Infection Recommendations: 2023 Update. Advances In Peritoneal Dialysis 2023, 43: 201-219. PMID: 37232412, DOI: 10.1177/08968608231172740.Peer-Reviewed Original ResearchConceptsDialysis catheter-related infectionsExit-site infection rateAntibiotic treatment durationCatheter exit siteExit-site infectionDuration of therapyCatheter-related infectionsImportant risk factorExit siteCatheter lossCatheter removalTunnel infectionSite infectionCuff removalAntibiotic creamCatheter interventionRisk factorsTreatment durationClinical monitoringInfection rateInfectionNew targetsNew recommendationsDurationPeritonitisDyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study
Hosier H, Lipkind H, Rasheed H, DeWan A, Rogne T. Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study. Hypertension 2023, 80: 1067-1076. PMID: 36883459, DOI: 10.1161/hypertensionaha.122.20426.Peer-Reviewed Original ResearchConceptsRisk of preeclampsiaProtective effectCholesteryl Ester Transfer Protein InhibitionLack of effectMendelian randomization studyMendelian randomization analysisMaternal morbidityElevated HDLLeading causeLipid levelsObservational studyPreeclampsiaLipid measurementsReduced riskAncestry groupsPharmacological targetsRandomization studyHDLLDLRandomization analysisSingle nucleotide polymorphismsNew targetsDyslipidemiaRiskProtein inhibitionObesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network
Clark J, Garvey W, Niswender K, Schmidt A, Ahima R, Aleman J, Battarbee A, Beckman J, Bennett W, Brown N, Chandler‐Laney P, Cox N, Goldberg I, Habegger K, Harper L, Hasty A, Hidalgo B, Kim S, Locher J, Luther J, Maruthur N, Miller E, Sevick M, Wells Q. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. Journal Of The American Heart Association 2023, 12: e027693. PMID: 36752232, PMCID: PMC10111504, DOI: 10.1161/jaha.122.027693.Peer-Reviewed Original ResearchConceptsAmerican Heart AssociationHeart AssociationWeight loss interventionNovel therapeutic approachesVanderbilt University Medical CenterUniversity Medical CenterEffective therapeutic interventionsField of obesityResearch NetworkLoss interventionClinical trialsWorldwide prevalenceMedical CenterTherapeutic approachesObesityTherapeutic targetAnimal modelsJohns Hopkins University SchoolTherapeutic interventionsIndividual centersNew targetsUniversity of AlabamaOverweightUniversity SchoolInterventionScreening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch
Sadeeshkumar H, Balaji A, Sutherland A, Mootien S, Anthony K, Breaker R. Screening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch. Analytical Biochemistry 2023, 666: 115047. PMID: 36682579, PMCID: PMC11149561, DOI: 10.1016/j.ab.2023.115047.Peer-Reviewed Original ResearchConceptsHigh-throughput screenAutoinducer-2Reporter geneBacterial processesEssential bacterial processesGram-negative bacterial cellsQuorum sensing signalsΒ-galactosidase reporter geneSmall molecule inhibitorsAntibiotic drug discoveryNatural riboswitchesAntimicrobial drug developmentRNA elementsPhysiological signalingRiboswitchBacterial cellsMolecule inhibitorsS-adenosylmethionineEscherichia coliCritical functionsNew targetsGenesDrug discoverySmall moleculesPromising target
2022
High-resolution crystal structure and chemical screening reveal pantothenate kinase as a new target for antifungal development
Gihaz S, Gareiss P, Choi JY, Renard I, Pal AC, Surovsteva Y, Chiu JE, Thekkiniath J, Plummer M, Hungerford W, Montgomery ML, Hosford A, Adams EM, Lightfoot JD, Fox D, Ojo KK, Staker BL, Fuller K, Ben Mamoun C. High-resolution crystal structure and chemical screening reveal pantothenate kinase as a new target for antifungal development. Structure 2022, 30: 1494-1507.e6. PMID: 36167065, PMCID: PMC10042587, DOI: 10.1016/j.str.2022.09.001.Peer-Reviewed Original ResearchConceptsCrystal structureHigh-throughput chemical screenHigh-resolution crystal structuresAntifungal drug developmentHigh-affinity inhibitorsEukaryotic pathogensChemical screenNew compoundsSingle chemotypeFunctional analysisLigand bindingAntifungal developmentPantothenate phosphorylationFungal isolatesPantothenate kinaseNew targetsFungiPanKPromising targetEnzymeDrug developmentNew mechanismCatalysisBiosynthesisKinaseTraffic Patterns of the Migrating Endothelium: How Force Transmission Regulates Vascular Malformation and Functional Shunting During Angiogenic Remodelling
Edgar LT, Park H, Crawshaw JR, Osborne JM, Eichmann A, Bernabeu MO. Traffic Patterns of the Migrating Endothelium: How Force Transmission Regulates Vascular Malformation and Functional Shunting During Angiogenic Remodelling. Frontiers In Cell And Developmental Biology 2022, 10: 840066. PMID: 35663401, PMCID: PMC9160721, DOI: 10.3389/fcell.2022.840066.Peer-Reviewed Original ResearchCell polarityCell-cell adherens junctionsAngiogenic remodellingEndothelial cellsAggregation of cellsMixed populationRearrangement of cellsVascular patterningAdherens junctionsForce transmissionALK1 receptorCell migrationAbnormal remodellingNew targetsEC dynamicsCellsMouse retinaRemodellingMigrationPolarityPopulationMutationsDevelopment of an immunohistochemical assay for Siglec-15
Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Development of an immunohistochemical assay for Siglec-15. Laboratory Investigation 2022, 102: 771-778. PMID: 35459795, PMCID: PMC9253057, DOI: 10.1038/s41374-022-00785-9.Peer-Reviewed Original ResearchConceptsSiglec-15IHC assaysPD-L1PD-1/PD-L1 inhibitionPD-L1 blockadePD-L1 inhibitionHigh expressionFuture clinical trialsImmunoglobulin-type lectinsSiglec-15 expressionCompanion diagnostic assayPromising new targetTumor histologyImmunotherapeutic targetLung cancerImmune cellsClinical trialsNovel recombinant antibodiesCancer histologyImmunohistochemical assaysMyeloid cellsTumor typesScoring systemNew targetsHigh concordanceEmerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
Crane J, Shi Q, Xi Y, Lai J, Pham K, Wang H. Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma. Journal Of Clinical And Translational Pathology 2022, 2: 31-36. PMID: 36275841, PMCID: PMC9585478, DOI: 10.14218/jctp.2022.00004.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papillomavirusHuman papillomavirus-positive oropharyngeal squamous cell carcinomaHPV-positive oropharyngeal squamous cell carcinomaHPV-negative oropharyngeal squamous cell carcinomaActive human papillomavirusNew targetsLong-term survivalPotential new targetsDefinitive treatmentHPV 16Treatment optionsSurvival prognosisTumor prognosisAdvanced stageHealth responsePrecision treatmentPrecision medicinePatientsCarcinomaPrognosisTreatmentPathological research
2021
Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4
Jussila AR, Zhang B, Caves E, Kirti S, Steele M, Hamburg-Shields E, Lydon J, Ying Y, Lafyatis R, Rajagopalan S, Horsley V, Atit RP. Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. Journal Of Investigative Dermatology 2021, 142: 1597-1606.e9. PMID: 34808238, PMCID: PMC9120259, DOI: 10.1016/j.jid.2021.10.025.Peer-Reviewed Original ResearchConceptsWnt/β-catenin-responsive geneWnt activationExtracellular matrix homeostasisGenetic evidenceHuman fibrotic diseasesLipid-filled cellsFunctional mediatorsExtracellular matrixDermal adipocytesMatrix homeostasisGenetic modelsNew targetsWntKey targetMechanisms of fibrosisFibrotic diseasesTherapeutic avenuesDermal remodelingExtracellular matrix expansionExcessive accumulationRemodelingFibrosis severitySkin fibrosisFibrotic remodelingDPP4 inhibitorsTherapeutic Advances in Small Cell Lung Cancer Management
Newton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management. Current Cancer Research 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.Peer-Reviewed Original ResearchSmall cell lung cancer managementSmall cell lung cancer treatmentSmall cell lung cancerCell lung cancer managementCell lung cancer treatmentLung cancer managementCell lung cancerLung cancer treatmentRecalcitrant malignancySignificant management challengesLung cancerTherapeutic advancesCancer managementTherapeutic interventionsCancer treatmentNew targetsCell cycle regulationCycle regulationImmunotherapyMalignancyCancerDiseasePhysiciansEmerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyPathogenesis of CIPNTreatment of CIPNFirst-line chemotherapeutic agentNon-pharmacological therapeuticsCommon adverse eventsNon-pharmacological strategiesQuality of lifeAdverse eventsClinical outcomesCancer survivorsEffective intervention strategiesClinical trialsSide effectsChemotherapeutic agentsEffective interventionsVinca alkaloidsNew targetsIntervention strategiesNeuropathyPrior failureClinical researchersPlatinum compoundsTherapeutics
2020
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff M, O’Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports 2020, 22: 42. PMID: 32562016, PMCID: PMC7305248, DOI: 10.1007/s11926-020-00918-3.Peer-Reviewed Original ResearchConceptsSkin fibrosisNew targetsSSc interstitial lung diseaseAutoimmune connective tissue diseaseSystemic sclerosis therapyConnective tissue diseaseInterstitial lung diseaseCurrent ongoing trialsNew therapeutic targetsActivation of fibroblastsPotential new targetsReviewSystemic sclerosisSclerosis therapyOngoing trialsTissue diseaseLung diseaseClinical trialsTherapeutic targetRate of declineDisease pathogenesisPhase IIIPhase IIFibrosisNew hopeDisease
2019
BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications
Weathington N, O’Brien M, Radder J, Whisenant TC, Bleecker ER, Busse WW, Erzurum SC, Gaston B, Hastie A, Jarjour N, Meyers D, Milosevic J, Moore W, Tedrow J, Trudeau J, Wong H, Wu W, Kaminski N, Wenzel S, Modena B. BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications. American Journal Of Respiratory And Critical Care Medicine 2019, 200: 837-856. PMID: 31161938, PMCID: PMC6812436, DOI: 10.1164/rccm.201811-2221oc.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AgonistsAdultAsthmaBronchoalveolar Lavage FluidCase-Control StudiesCyclic AMPEosinophilsEpithelial CellsFemaleGene ExpressionHumansIn Vitro TechniquesLymphocytesMacrophages, AlveolarMaleNeutrophilsSequence Analysis, RNASeverity of Illness IndexSignal TransductionTHP-1 CellsConceptsCell gene expressionGene expressionAirway epithelial cell gene expressionEpithelial cell gene expressionGlobal gene expressionCellular gene expressionCell expression profilesAsthma susceptibility lociProtein levelsSystem-wide analysisExpression networksImportant disease mechanismCoexpression networkCellular milieuExpression changesExpression profilesSusceptibility lociCellular modelDisease mechanismsBiomolecular mechanismsNew targetsRobust upregulationSample traitsGenesExpressionAberrant splicing contributes to severe α-spectrin-linked congenital hemolytic anemia
Gallagher PG, Maksimova Y, Lezon-Geyda K, Newburger PE, Medeiros D, Hanson RD, Rothman J, Israels S, Wall DA, Sidonio RF, Sieff C, Gowans LK, Mittal N, Rivera-Santiago R, Speicher DW, Baserga SJ, Schulz VP. Aberrant splicing contributes to severe α-spectrin-linked congenital hemolytic anemia. Journal Of Clinical Investigation 2019, 129: 2878-2887. PMID: 31038472, PMCID: PMC6597203, DOI: 10.1172/jci127195.Peer-Reviewed Original ResearchConceptsRecessive hereditary spherocytosisSplice acceptor siteHuman genetic diseasesMRNA stability studiesAberrant splicing contributesSplicing contributesWhole-genome sequencingSplicing analysisHereditary pyropoikilocytosisTermination codonNull allelesGenome sequencingWhole-exome sequencingBranch pointsNumerous mutationsGenetic diseasesLinkage disequilibriumMRNA transcriptsΑ-spectrinMinigene studiesAcceptor sitesMutationsExome sequencingNew targetsPharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUDChapter 6 Addiction: Informing drug abuse interventions with brain networks
Steele V, Ding X, Ross T. Chapter 6 Addiction: Informing drug abuse interventions with brain networks. 2019, 101-122. DOI: 10.1016/b978-0-12-813838-0.00006-6.ChaptersSubstance use disordersBrain networksNoninvasive brain stimulationDefault mode networkExecutive control networkRisk factorsEffective treatmentBrain stimulationUse disordersClinical modelBrain diseasesDiseaseEffective interventionsNew targetsInterventionAbuse interventionsReward processingFocal manipulation
2018
Astrocytes and Glutamine Synthetase in Epileptogenesis
Eid T, Lee T, Patrylo P, Zaveri HP. Astrocytes and Glutamine Synthetase in Epileptogenesis. Journal Of Neuroscience Research 2018, 97: 1345-1362. PMID: 30022509, PMCID: PMC6338538, DOI: 10.1002/jnr.24267.Peer-Reviewed Original ResearchConceptsMesial temporal lobe epilepsyTemporal lobe epilepsyLobe epilepsyAstrocytic glutamine synthetaseRole of astrocytesPotassium channel Kir4.1Important causative factorExcitatory amino acid transporters EAAT1Antiepileptogenic interventionsEpileptogenic insultAntiepileptogenic therapiesEpilepsy developmentChannel Kir4.1Aquaporin-4EpilepsyCausative factorsTransporters EAAT1New targetsSuch interventionsTransporters MCT1DysfunctionAstrocytesMetabolic mechanismsGlutamine synthetaseDownstream effectsMolecular regulations and therapeutic targets of Gaucher disease
Chen Y, Sud N, Hettinghouse A, Liu C. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine & Growth Factor Reviews 2018, 41: 65-74. PMID: 29699937, PMCID: PMC8108120, DOI: 10.1016/j.cytogfr.2018.04.003.Peer-Reviewed Original ResearchConceptsGaucher diseaseHeat shock proteinsProper foldingMolecular regulationActivity of GCaseLysosomal localizationShock proteinsCommon lysosomal storage diseaseLysosomal appearanceIon channelsCalcium ion channelsLysosomal accumulationSaposin CLysosomal storage diseaseSubstrate glucosylceramideInflammatory mediatorsProinflammatory moleculesNew targetsPathogenic mechanismsTherapeutic targetGCaseNovel moleculesSmall moleculesDiseaseStorage disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply